Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Engineered Skin “Living Sensor Display” Lights Up for Biological Monitoring

Wearable health devices, such as smartwatches, have become commonplace and enable continuous monitoring of physiological signals at the skin’s surface. A research team led by scientists at Tokyo City University and at The University of Tokyo, collaborating wit

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Wearable health devices, such as smartwatches, have become commonplace and enable continuous monitoring of physiological signals at the skin’s surface. A research team led by scientists at Tokyo City University and at The University of Tokyo, collaborating with researchers at RIKEN and at Canon Medical Systems Co., now reports on the development of a biohybrid approach that works by transforming engineered skin to a visible indicator of internal biological states.

The ”living sensor display” is an engineered skin graft that fluoresces in response to specific internal biomarkers, such as those associated with inflammation. The system leverages the body’s natural skin regeneration to support long-term biomarker monitoring, providing a visual readout without blood sampling after implantation. Headed by Hiroyuki Fujita, PhD, distinguished professor of Tokyo City University (professor emeritus, The University of Tokyo), the scientists carried out tests in live mice, demonstrating that the transplants were able to continually monitor inflammatory cytokines.

Development of the tissue engineered skin living sensor is described in a paper in Nature Communications, titled, “Living sensor display implanted on skin for long-term biomarker monitoring.” In their report investigators concluded, “This living sensor display holds promise for advancing health monitoring and disease prevention strategies by enabling continuous, sensitive, and specific in vivo biomarker tracking.”

Measuring biomarkers, such as blood glucose levels or presence of inflammatory cytokines, can play an important role in early disease prevention, provide insights into disease progression and personal health, and in the managing lifestyle of related diseases, the authors noted. Monitoring such internal biomarkers has traditionally relied on blood sampling, or externally attached sensors that operate only for limited duration. “Conventionally, biomarker detection has primarily been achieved through intermittent blood sampling, which allows for accurate measurements,” the team noted. “However, it is not suitable for long-term continuous monitoring owing to its invasive nature.”

Fujita added, “Conventional approaches are often invasive or provide only snapshots in time. Our goal was to explore a biologically integrated system that enables continuous sensing and intuitive interpretation, even at home.”

Wearable devices can enable long-term, continuous monitoring of health-related biomarkers using sweat, saliva, tears or interstitial fluid, the scientists pointed out. “However, no method is able to monitor biomarkers within the body with high selectivity and sensitivity over long durations.”

To develop the living sensor display technology the researchers used epidermal stem cells known as skin keratinocyte stem cells (KSCs), which naturally maintain and renew the skin throughout life. By genetically engineering these cells to respond to inflammatory signaling, the team generated skin tissue that expresses enhanced green fluorescent protein (EGFP) in response to specific inflammation-related signals.

They focused on monitoring the inflammatory cytokine tumor necrosis factor-α (TNF-α). “To detect TNF-α, we first genetically engineered human epidermal keratinocytes (NHEK), including KSCs to express NF-κB-EGFP, which is activated by TNF-α stimulation,” they wrote. “Next, we used these cells to construct a tissue-engineered skin model and verify its concentration-dependent responsiveness to TNF-α stimulation.”

The researchers showed that, when transplanted onto mice, the engineered skin engrafted and functionally integrated with the host tissue. When inflammation was induced, the grafted area emitted green fluorescence, translating internal molecular signals to an external optical signal. “The fluorescent protein expressed within the transplanted cells emitted high intensity light that was visible from outside the skin,” the scientists commented. Because the sensor comprises living epidermal stem cells, it is maintained through the skin’s natural turnover. “Furthermore, the internal movement and differentiation of cells within the skin due to cellular turnover allows for long-term continuous monitoring without altering the illuminated area,” they added.

The study confirmed that the area of skin demonstrating the fluorescent response was maintained for more than 200 days after grafting. Co-author professor Shoji Takeuchi, PhD, at The University of Tokyo, noted, “Unlike conventional devices that require power sources or periodic replacement, this system is biologically maintained by the body itself. In our experiments, the sensor functionality was preserved for over 200 days, as the engineered stem cells continuously regenerated the epidermis.”

The study demonstrates a proof of concept for long-term, biologically integrated sensing without batteries, wiring, or active user operation. Although this work focused on inflammatory signaling, the underlying strategy is adaptable. By modifying the molecular targets, similar engineered skin constructs could be designed to respond to other physiological or metabolic cues. “By changing the receptors, it is conceivable to detect various target substances similarly in the future,” the scientists stated.

They further suggest that such technology could have applications beyond human healthcare, in areas including veterinary medicine, where visual indicators of health status may aid the early detection of disease in animals unable to communicate symptoms. “Unlike conventional wearable sensor technologies, this method enables the long-term, real-time acquisition of minute biochemical signals, with potential applications ranging from health management and early disease detection to veterinary medicine and livestock monitoring,” the authors reported.

Although still at an early preclinical stage, this work offers a biologically grounded approach for interfacing living tissues with sensing functions, blurring the boundary between biological systems and engineered devices. While noting remaining challenges, the researchers wrote, “In conclusion, our Living Sensor Display leverages the characteristics of receptors to detect unstable and minute biomarkers in vivo with high sensitivity and continuity. By further investigating their invasiveness and safety, engineered cells can be implanted into the body, paving the way for a paradigm in healthcare that includes long term disease monitoring and health management through early detection.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →